Cargando…

The clinical application of metagenomic next-generation sequencing in sepsis of immunocompromised patients

BACKGROUND: Metagenomic next-generation sequencing (mNGS) was commonly applied given its ability to identify and type all infections without depending upon culture and to retrieve all DNA with unbiasedness. In this study, we strive to compare outcomes of mNGS with conventional culture methods in adu...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Xingxing, Liang, Shunda, Zhang, Dan, He, Miao, Zhang, Hong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10164957/
https://www.ncbi.nlm.nih.gov/pubmed/37168393
http://dx.doi.org/10.3389/fcimb.2023.1170687
_version_ 1785038160891215872
author Li, Xingxing
Liang, Shunda
Zhang, Dan
He, Miao
Zhang, Hong
author_facet Li, Xingxing
Liang, Shunda
Zhang, Dan
He, Miao
Zhang, Hong
author_sort Li, Xingxing
collection PubMed
description BACKGROUND: Metagenomic next-generation sequencing (mNGS) was commonly applied given its ability to identify and type all infections without depending upon culture and to retrieve all DNA with unbiasedness. In this study, we strive to compare outcomes of mNGS with conventional culture methods in adults with sepsis, investigate the differences between the immunocompromised and control group, and assess the clinical effects of mNGS. METHODS: In our study, 308 adult sepsis patients were included. We used both mNGS and conventional culture methods to analyze diagnostic results, pathogens, and sample types. The correlation between some laboratory tests and the frequency of pathogens by groups was also analyzed. Furthermore, the clinical impacts of mNGS were estimated. RESULTS: 308 samples were assigned to an immunocompromised group (92/308,29.9%) and a control group (216/308,70.1%). There was the sensitivity of mNGS considered greater than that of the culture method in all samples (88.0% vs 26.3%; P <​ 0.001), in the immunocompromised group (91.3% vs 26.1%; P <​ 0.001), and the control group (86.6% vs 26.4%; P <​ 0.001), particularly in all sample types of blood (P <​ 0.001), BALF (P <​ 0.001), CSF (P <​ 0.001), sputum (P <​ 0.001) and ascitic fluid (P = 0.008). When examining the mNGS results between groups, Pneumocystis jirovecii (P < 0.001), Mucoraceae (P = 0.014), and Klebsiella (P = 0.045) all showed significant differences. On the whole, mNGS detected more pathogens than culture methods (111 vs 25), found 89 organisms that were continuously overlooked in entire samples by culture methods, and showed a favorable positive clinical effect in 76.3% (235 of 308) of patients. In 185 (60.1%) patients, mNGS prompted a modification in the course of management, which included antibiotic de-escalation in 61(19.8%) patients. CONCLUSIONS: The research discovered that mNGS was more sensitive than the culture method, particularly in samples of blood, BALF, CSF, sputum, and ascitic fluid. When examining the mNGS results, Pneumocystis jirovecii and Mucoraceae were the pathogens seen more commonly in immunocompromised patients with sepsis, which required more attention from clinicians. There was a substantial benefit of mNGS in enhancing the diagnosis of sepsis and advancing patient treatment.
format Online
Article
Text
id pubmed-10164957
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-101649572023-05-09 The clinical application of metagenomic next-generation sequencing in sepsis of immunocompromised patients Li, Xingxing Liang, Shunda Zhang, Dan He, Miao Zhang, Hong Front Cell Infect Microbiol Cellular and Infection Microbiology BACKGROUND: Metagenomic next-generation sequencing (mNGS) was commonly applied given its ability to identify and type all infections without depending upon culture and to retrieve all DNA with unbiasedness. In this study, we strive to compare outcomes of mNGS with conventional culture methods in adults with sepsis, investigate the differences between the immunocompromised and control group, and assess the clinical effects of mNGS. METHODS: In our study, 308 adult sepsis patients were included. We used both mNGS and conventional culture methods to analyze diagnostic results, pathogens, and sample types. The correlation between some laboratory tests and the frequency of pathogens by groups was also analyzed. Furthermore, the clinical impacts of mNGS were estimated. RESULTS: 308 samples were assigned to an immunocompromised group (92/308,29.9%) and a control group (216/308,70.1%). There was the sensitivity of mNGS considered greater than that of the culture method in all samples (88.0% vs 26.3%; P <​ 0.001), in the immunocompromised group (91.3% vs 26.1%; P <​ 0.001), and the control group (86.6% vs 26.4%; P <​ 0.001), particularly in all sample types of blood (P <​ 0.001), BALF (P <​ 0.001), CSF (P <​ 0.001), sputum (P <​ 0.001) and ascitic fluid (P = 0.008). When examining the mNGS results between groups, Pneumocystis jirovecii (P < 0.001), Mucoraceae (P = 0.014), and Klebsiella (P = 0.045) all showed significant differences. On the whole, mNGS detected more pathogens than culture methods (111 vs 25), found 89 organisms that were continuously overlooked in entire samples by culture methods, and showed a favorable positive clinical effect in 76.3% (235 of 308) of patients. In 185 (60.1%) patients, mNGS prompted a modification in the course of management, which included antibiotic de-escalation in 61(19.8%) patients. CONCLUSIONS: The research discovered that mNGS was more sensitive than the culture method, particularly in samples of blood, BALF, CSF, sputum, and ascitic fluid. When examining the mNGS results, Pneumocystis jirovecii and Mucoraceae were the pathogens seen more commonly in immunocompromised patients with sepsis, which required more attention from clinicians. There was a substantial benefit of mNGS in enhancing the diagnosis of sepsis and advancing patient treatment. Frontiers Media S.A. 2023-04-24 /pmc/articles/PMC10164957/ /pubmed/37168393 http://dx.doi.org/10.3389/fcimb.2023.1170687 Text en Copyright © 2023 Li, Liang, Zhang, He and Zhang https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Cellular and Infection Microbiology
Li, Xingxing
Liang, Shunda
Zhang, Dan
He, Miao
Zhang, Hong
The clinical application of metagenomic next-generation sequencing in sepsis of immunocompromised patients
title The clinical application of metagenomic next-generation sequencing in sepsis of immunocompromised patients
title_full The clinical application of metagenomic next-generation sequencing in sepsis of immunocompromised patients
title_fullStr The clinical application of metagenomic next-generation sequencing in sepsis of immunocompromised patients
title_full_unstemmed The clinical application of metagenomic next-generation sequencing in sepsis of immunocompromised patients
title_short The clinical application of metagenomic next-generation sequencing in sepsis of immunocompromised patients
title_sort clinical application of metagenomic next-generation sequencing in sepsis of immunocompromised patients
topic Cellular and Infection Microbiology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10164957/
https://www.ncbi.nlm.nih.gov/pubmed/37168393
http://dx.doi.org/10.3389/fcimb.2023.1170687
work_keys_str_mv AT lixingxing theclinicalapplicationofmetagenomicnextgenerationsequencinginsepsisofimmunocompromisedpatients
AT liangshunda theclinicalapplicationofmetagenomicnextgenerationsequencinginsepsisofimmunocompromisedpatients
AT zhangdan theclinicalapplicationofmetagenomicnextgenerationsequencinginsepsisofimmunocompromisedpatients
AT hemiao theclinicalapplicationofmetagenomicnextgenerationsequencinginsepsisofimmunocompromisedpatients
AT zhanghong theclinicalapplicationofmetagenomicnextgenerationsequencinginsepsisofimmunocompromisedpatients
AT lixingxing clinicalapplicationofmetagenomicnextgenerationsequencinginsepsisofimmunocompromisedpatients
AT liangshunda clinicalapplicationofmetagenomicnextgenerationsequencinginsepsisofimmunocompromisedpatients
AT zhangdan clinicalapplicationofmetagenomicnextgenerationsequencinginsepsisofimmunocompromisedpatients
AT hemiao clinicalapplicationofmetagenomicnextgenerationsequencinginsepsisofimmunocompromisedpatients
AT zhanghong clinicalapplicationofmetagenomicnextgenerationsequencinginsepsisofimmunocompromisedpatients